-
1
-
-
84867497463
-
KDOQI clinical practice guideline for diabetes and CKD: 2012 update
-
National Kidney Foundation.
-
National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis 2012;60: 850-86.
-
(2012)
Am J Kidney Dis
, vol.60
, pp. 850-886
-
-
-
2
-
-
84925489733
-
Management of hyperglycaemia in type 2 diabetes, 2015: A patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes
-
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2015;58:429-42.
-
(2015)
Diabetologia
, vol.58
, pp. 429-442
-
-
Inzucchi, S.E.1
Bergenstal, R.M.2
Buse, J.B.3
-
4
-
-
84901768284
-
Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes
-
Holman RR, Sourij H, Califf RM. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet 2014;383:2008-17.
-
(2014)
Lancet
, vol.383
, pp. 2008-2017
-
-
Holman, R.R.1
Sourij, H.2
Califf, R.M.3
-
5
-
-
84970922145
-
-
http://www.safeguard-diabetes.org.
-
-
-
-
6
-
-
35748957503
-
The physiology of glucagon-like peptide 1
-
Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007;87:1409-39.
-
(2007)
Physiol Rev
, vol.87
, pp. 1409-1439
-
-
Holst, J.J.1
-
7
-
-
0037045845
-
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: A parallel-group study
-
Zander M, Madsbad S, Madsen JL, et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359:824-30.
-
(2002)
Lancet
, vol.359
, pp. 824-830
-
-
Zander, M.1
Madsbad, S.2
Madsen, J.L.3
-
8
-
-
0022617246
-
Reduced incretin effect in type 2 (non-insulin-dependent) diabetes
-
Nauck M, Stöckmann F, Ebert R, et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986;29:46-52.
-
(1986)
Diabetologia
, vol.29
, pp. 46-52
-
-
Nauck, M.1
Stöckmann, F.2
Ebert, R.3
-
9
-
-
67651173077
-
Incretin-based therapies for type 2 diabetes mellitus
-
Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009;5:262-9.
-
(2009)
Nat Rev Endocrinol
, vol.5
, pp. 262-269
-
-
Lovshin, J.A.1
Drucker, D.J.2
-
10
-
-
84897852105
-
GLP-1 receptor localization in monkey and human tissue: Novel distribution revealed with extensively validated monoclonal antibody
-
Pyke C, Heller RS, Kirk RK, et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 2014;155:1280-90.
-
(2014)
Endocrinology
, vol.155
, pp. 1280-1290
-
-
Pyke, C.1
Heller, R.S.2
Kirk, R.K.3
-
11
-
-
34250635159
-
GLP-1 receptor expression in human tumors and human normal tissues: Potential for in vivo targeting
-
Körner M, Stöckli M, Waser B, et al. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med 2007;48:736-43.
-
(2007)
J Nucl Med
, vol.48
, pp. 736-743
-
-
Körner, M.1
Stöckli, M.2
Waser, B.3
-
12
-
-
84873554686
-
Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: Systematic review and meta-analysis
-
pii: e001986
-
Robinson L, Holt T, Rees K. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open 2013;3:pii: e001986.
-
(2013)
BMJ Open
, vol.3
-
-
Robinson, L.1
Holt, T.2
Rees, K.3
-
13
-
-
84912523371
-
Dipeptidyl-peptidase-4 inhibitors and heart failure: Class effect substance-specific effect or chance effect?
-
Standl E, Erbach M, Schnell O. Dipeptidyl-peptidase-4 inhibitors and heart failure: class effect, substance-specific effect, or chance effect? Curr Treat Options Cardiovasc Med 2014;16:353.
-
(2014)
Curr Treat Options Cardiovasc Med
, vol.16
, pp. 353
-
-
Standl, E.1
Erbach, M.2
Schnell, O.3
-
15
-
-
42949089442
-
Exenatide and rare adverse events
-
discussion 1971-2
-
Ahmad SR, Swann J. Exenatide and rare adverse events. N Engl J Med 2008;358:1970-1; discussion 1971-2.
-
(2008)
N Engl J Med
, vol.358
, pp. 1970-1971
-
-
Ahmad, S.R.1
Swann, J.2
-
16
-
-
84876063836
-
Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: A population-based matched case-control study
-
Singh S, Chang H-Y, Richards TM, et al. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med2013;173:534-9.
-
(2013)
JAMA Intern Med
, vol.173
, pp. 534-539
-
-
Singh, S.1
Chang, H.-Y.2
Richards, T.M.3
-
17
-
-
79959559653
-
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
-
Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011; 141:150-6.
-
(2011)
Gastroenterology
, vol.141
, pp. 150-156
-
-
Elashoff, M.1
Matveyenko, A.V.2
Gier, B.3
-
18
-
-
84856877681
-
Resting heart rate is associated with cardiovascular and all-cause mortality after adjusting for inflammatory markers: The Copenhagen City Heart Study
-
Jensen MT, Marott JL, Allin KH, et al. Resting heart rate is associated with cardiovascular and all-cause mortality after adjusting for inflammatory markers: the Copenhagen City Heart Study. Eur J Prev Cardiol 2012;19:102-8.
-
(2012)
Eur J Prev Cardiol
, vol.19
, pp. 102-108
-
-
Jensen, M.T.1
Marott, J.L.2
Allin, K.H.3
-
19
-
-
0032714917
-
Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats
-
Barragán JM, Eng J, Rodríguez R, et al. Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats. Am J Physiol1999;277:E784-91.
-
(1999)
Am J Physiol
, vol.277
, pp. E784-E791
-
-
Barragán, J.M.1
Eng, J.2
Rodríguez, R.3
-
20
-
-
31144446219
-
Mesenteric vasoconstriction and hindquarters vasodilatation accompany the pressor actions of exendin-4 in conscious rats
-
Gardiner SM, March JE, Kemp PA, et al. Mesenteric vasoconstriction and hindquarters vasodilatation accompany the pressor actions of exendin-4 in conscious rats. J Pharmacol Exp Ther 2006;316:852-9.
-
(2006)
J Pharmacol Exp Ther
, vol.316
, pp. 852-859
-
-
Gardiner, S.M.1
March, J.E.2
Kemp, P.A.3
-
21
-
-
84867254999
-
Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and-independent actions
-
Shigeta T, Aoyama M, Bando YK, et al. Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and-independent actions. Circulation 2012;126:1838-51.
-
(2012)
Circulation
, vol.126
, pp. 1838-1851
-
-
Shigeta, T.1
Aoyama, M.2
Bando, Y.K.3
-
22
-
-
84862521094
-
Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: A double-blind, randomised controlled clinical trial of efficacy and safety
-
Nathanson D, Ullman B, Löfström U, et al. Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety. Diabetologia 2012;55:926-35.
-
(2012)
Diabetologia
, vol.55
, pp. 926-935
-
-
Nathanson, D.1
Ullman, B.2
Löfström, U.3
-
23
-
-
84883765959
-
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
-
Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-26.
-
(2013)
N Engl J Med
, vol.369
, pp. 1317-1326
-
-
Scirica, B.M.1
Bhatt, D.L.2
Braunwald, E.3
-
24
-
-
84932636107
-
Increased risk of hospitalization for heart failure with newly prescribed dipeptidyl peptidase-4 inhibitors and pioglitazone using the Korean Health Insurance Claims Database
-
Suh S, Seo GH, Jung CH, et al. Increased risk of hospitalization for heart failure with newly prescribed dipeptidyl peptidase-4 inhibitors and pioglitazone using the Korean Health Insurance Claims Database. Diabetes Metab J 2015;39:247-52.
-
(2015)
Diabetes Metab J
, vol.39
, pp. 247-252
-
-
Suh, S.1
Seo, G.H.2
Ch, J.3
-
25
-
-
8544258807
-
Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease
-
Nyström T, Gutniak MK, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004;287:E1209-15.
-
(2004)
Am J Physiol Endocrinol Metab
, vol.287
, pp. E1209-E1215
-
-
Nyström, T.1
Gutniak, M.K.2
Zhang, Q.3
-
26
-
-
79956119675
-
The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an 'endothelial resistance' to glucagon-like peptide 1 in diabetes
-
Ceriello A, Esposito K, Testa R, et al. The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an 'endothelial resistance' to glucagon-like peptide 1 in diabetes. Diabetes Care 2011;34:697-702.
-
(2011)
Diabetes Care
, vol.34
, pp. 697-702
-
-
Ceriello, A.1
Esposito, K.2
Testa, R.3
-
27
-
-
84893424204
-
A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis
-
Tashiro Y, Sato K, Watanabe T, et al. A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis. Peptides 2014;54:19-26.
-
(2014)
Peptides
, vol.54
, pp. 19-26
-
-
Tashiro, Y.1
Sato, K.2
Watanabe, T.3
-
28
-
-
84895762544
-
Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study
-
Rizzo M, Chandalia M, Patti AM, et al. Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study. Cardiovasc Diabetol 2014; 13:49.
-
(2014)
Cardiovasc Diabetol
, vol.13
, pp. 49
-
-
Rizzo, M.1
Chandalia, M.2
Patti, A.M.3
-
29
-
-
79955692561
-
Glucagon-like peptide-1 (GLP-1), immediately prior to reperfusion, decreases neutrophil activation and reduces myocardial infarct size in rodents
-
Dokken BB, La Bonte LR, Davis-Gorman G, et al. Glucagon-like peptide-1 (GLP-1), immediately prior to reperfusion, decreases neutrophil activation and reduces myocardial infarct size in rodents. Horm Metab Res 2011;43:300-5.
-
(2011)
Horm Metab Res
, vol.43
, pp. 300-305
-
-
Dokken, B.B.1
La Bonte, L.R.2
Davis-Gorman, G.3
-
30
-
-
58949084130
-
Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury
-
Timmers L, Henriques JPS, de Kleijn DPV, et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 2009;53:501-10.
-
(2009)
J Am Coll Cardiol
, vol.53
, pp. 501-510
-
-
Timmers, L.1
Jps, H.2
De Kleijn DPV3
-
31
-
-
84923165949
-
Pre-treatment with glucagon-like Peptide-1 protects against ischemic left ventricular dysfunction and stunning without a detected difference in myocardial substrate utilization
-
McCormick LM, Hoole SP, White PA, et al. Pre-treatment with glucagon-like Peptide-1 protects against ischemic left ventricular dysfunction and stunning without a detected difference in myocardial substrate utilization. JACC Cardiovasc Interv 2015;8:292-301.
-
(2015)
JACC Cardiovasc Interv
, vol.8
, pp. 292-301
-
-
McCormick, L.M.1
Hoole, S.P.2
White, P.A.3
-
32
-
-
84860390563
-
A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans
-
Read PA, Hoole SP, White PA, et al. A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans. Circ Cardiovasc Interv 2011;4:266-72.
-
(2011)
Circ Cardiovasc Interv
, vol.4
, pp. 266-272
-
-
Read, P.A.1
Hoole, S.P.2
White, P.A.3
-
33
-
-
84863560602
-
Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction
-
Lønborg J, Vejlstrup N, Kelbæk H, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 2012;33:1491-9.
-
(2012)
Eur Heart J
, vol.33
, pp. 1491-1499
-
-
Lønborg, J.1
Vejlstrup, N.2
Kelbæk, H.3
-
34
-
-
84892743922
-
Effects of glucagon-like peptide-1 receptor agonists on renal function
-
Filippatos TD, Elisaf MS. Effects of glucagon-like peptide-1 receptor agonists on renal function. World J Diabetes 2013;4:190-201.
-
(2013)
World J Diabetes
, vol.4
, pp. 190-201
-
-
Filippatos, T.D.1
Elisaf, M.S.2
-
35
-
-
53349172746
-
Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use
-
Kao DP, Kohrt HE, Kugler J. Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. Diabet Med 2008;25:1229-30.
-
(2008)
Diabet Med
, vol.25
, pp. 1229-1230
-
-
Kao, D.P.1
Kohrt, H.E.2
Kugler, J.3
-
36
-
-
84862777558
-
Exenatide and sitagliptin are not associated with increased risk of acute renal failure: A retrospective claims analysis
-
Pendergrass M, Fenton C, Haffner SM, et al. Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis. Diabetes Obes Metab 2012;14:596-600.
-
(2012)
Diabetes Obes Metab
, vol.14
, pp. 596-600
-
-
Pendergrass, M.1
Fenton, C.2
Haffner, S.M.3
-
37
-
-
0038202937
-
Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats
-
Yu M, Moreno C, Hoagland KM, et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens 2003;21:1125-35.
-
(2003)
J Hypertens
, vol.21
, pp. 1125-1135
-
-
Yu, M.1
Moreno, C.2
Hoagland, K.M.3
-
38
-
-
77955106477
-
The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats
-
Liu Q, Adams L, Broyde A, et al. The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats. Cardiovasc Diabetol 2010;9:32.
-
(2010)
Cardiovasc Diabetol
, vol.9
, pp. 32
-
-
Liu, Q.1
Adams, L.2
Broyde, A.3
-
39
-
-
34047205064
-
Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice
-
Park CW, Kim HW, Ko SH, et al. Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. J Am Soc Nephrol 2007;18:1227-38.
-
(2007)
J Am Soc Nephrol
, vol.18
, pp. 1227-1238
-
-
Park, C.W.1
Kim, H.W.2
Ko, S.H.3
-
40
-
-
84895072279
-
The gut-renal axis: Do incretin-based agents confer renoprotection in diabetes?
-
Muskiet MHA, Smits MM, Morsink LM, et al. The gut-renal axis: do incretin-based agents confer renoprotection in diabetes? Nat Rev Nephrol 2014;10:88-103.
-
(2014)
Nat Rev Nephrol
, vol.10
, pp. 88-103
-
-
Mha, M.1
Smits, M.M.2
Morsink, L.M.3
-
41
-
-
77955573674
-
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): A randomised trial
-
Bergenstal RM, Wysham C, Macconell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010;376:431-9.
-
(2010)
Lancet
, vol.376
, pp. 431-439
-
-
Bergenstal, R.M.1
Wysham, C.2
Macconell, L.3
-
44
-
-
84890476805
-
Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction
-
Groop P-H, Cooper ME, Perkovic V, et al. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care 2013;36:3460-8.
-
(2013)
Diabetes Care
, vol.36
, pp. 3460-3468
-
-
Groop, P.-H.1
Cooper, M.E.2
Perkovic, V.3
-
45
-
-
84942789301
-
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus and moderate or severe renal impairment: Observations from the SAVOR-TIMI 53 trial
-
Udell JA, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 trial. Diabetes Care 2015;38:696-705.
-
(2015)
Diabetes Care
, vol.38
, pp. 696-705
-
-
Udell, J.A.1
Bhatt, D.L.2
Braunwald, E.3
-
46
-
-
84928601182
-
Pleiotropic effects of type 2 diabetes management strategies on renal risk factors
-
Muskiet MHA, Tonneijck L, Smits MM, et al. Pleiotropic effects of type 2 diabetes management strategies on renal risk factors. Lancet Diabetes Endocrinol 2015;3:367-81.
-
(2015)
Lancet Diabetes Endocrinol
, vol.3
, pp. 367-381
-
-
Mha, M.1
Tonneijck, L.2
Smits, M.M.3
-
47
-
-
72449157026
-
Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas
-
Nachnani JS, Bulchandani DG, Nookala A, et al. Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia 2010;53:153-9.
-
(2010)
Diabetologia
, vol.53
, pp. 153-159
-
-
Nachnani, J.S.1
Bulchandani, D.G.2
Nookala, A.3
-
48
-
-
72449148137
-
Glucagon-like peptide-1 therapy and the exocrine pancreas: Innocent bystander or friendly fire?
-
Butler PC, Matveyenko AV, Dry S, et al. Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire? Diabetologia 2010;53:1-6.
-
(2010)
Diabetologia
, vol.53
, pp. 1-6
-
-
Butler, P.C.1
Matveyenko, A.V.2
Dry, S.3
-
49
-
-
84930629862
-
Incretin-based therapy and risk of acute pancreatitis: A Nationwide Population-Based Case-Control Study
-
Thomsen RW, Pedersen L, Møller N, et al. Incretin-based therapy and risk of acute pancreatitis: a Nationwide Population-Based Case-Control Study. Diabetes Care 2015;38:1089-98.
-
(2015)
Diabetes Care
, vol.38
, pp. 1089-1098
-
-
Thomsen, R.W.1
Pedersen, L.2
Møller, N.3
-
50
-
-
84896731936
-
Pancreatic safety of incretin-based drugs-FDA and EMA assessment
-
Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs-FDA and EMA assessment. N Engl J Med 2014;370:794-7.
-
(2014)
N Engl J Med
, vol.370
, pp. 794-797
-
-
Egan, A.G.1
Blind, E.2
Dunder, K.3
-
51
-
-
84918828271
-
Chronic continuous exenatide infusion does not cause pancreatic inflammation and ductal hyperplasia in non-human primates
-
Fiorentino TV, Owston M, Abrahamian G, et al. Chronic continuous exenatide infusion does not cause pancreatic inflammation and ductal hyperplasia in non-human primates. Am J Pathol 2015;185:139-50.
-
(2015)
Am J Pathol
, vol.185
, pp. 139-150
-
-
Fiorentino, T.V.1
Owston, M.2
Abrahamian, G.3
-
52
-
-
0037667613
-
Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes
-
Meier JJ, Gallwitz B, Salmen S, et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 2003;88:2719-25.
-
(2003)
J Clin Endocrinol Metab
, vol.88
, pp. 2719-2725
-
-
Meier, J.J.1
Gallwitz, B.2
Salmen, S.3
-
53
-
-
84956914555
-
Incretin-based therapies for the treatment of nonalcoholic fatty liver disease: A systematic review and meta-analysis
-
Published Online First: 25 June 2015
-
Carbone LJ, Angus PW, Yeomans ND. Incretin-based therapies for the treatment of nonalcoholic fatty liver disease: a systematic review and meta-analysis. J Gastroenterol Hepatol 2015. Published Online First: 25 June 2015. doi:10.1111/jgh.13026
-
J Gastroenterol Hepatol 2015
-
-
Carbone, L.J.1
Angus, P.W.2
Yeomans, N.D.3
-
54
-
-
57649166909
-
Clinical trial: The glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: A randomized, placebo-controlled, double-blind study
-
Hellström PM, Hein J, Bytzer P, et al. Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study. Aliment Pharmacol Ther 2009;29:198-206.
-
(2009)
Aliment Pharmacol Ther
, vol.29
, pp. 198-206
-
-
Hellström, P.M.1
Hein, J.2
Bytzer, P.3
-
55
-
-
80052812653
-
Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function
-
Marathe CS, Rayner CK, Jones KL, et al. Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function. Exp Diabetes Res 2011;2011:279530.
-
(2011)
Exp Diabetes Res
, vol.2011
, pp. 279530
-
-
Marathe, C.S.1
Rayner, C.K.2
Jones, K.L.3
-
56
-
-
0027533758
-
Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man
-
Wettergren A, Schjoldager B, Mortensen PE, et al. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993;38:665-73.
-
(1993)
Dig Dis Sci
, vol.38
, pp. 665-673
-
-
Wettergren, A.1
Schjoldager, B.2
Mortensen, P.E.3
-
57
-
-
0030962231
-
The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation
-
Wettergren A, Wojdemann M, Meisner S, et al. The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation. Gut 1997;40:597-601.
-
(1997)
Gut
, vol.40
, pp. 597-601
-
-
Wettergren, A.1
Wojdemann, M.2
Meisner, S.3
-
58
-
-
0024338802
-
GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans
-
Schjoldager BT, Mortensen PE, Christiansen J, et al. GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans. Dig Dis Sci 1989;34:703-8.
-
(1989)
Dig Dis Sci
, vol.34
, pp. 703-708
-
-
Schjoldager, B.T.1
Mortensen, P.E.2
Christiansen, J.3
-
59
-
-
84866701959
-
Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects
-
Keller J, Trautmann ME, Haber H, et al. Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects. Regul Pept 2012;179:77-83.
-
(2012)
Regul Pept
, vol.179
, pp. 77-83
-
-
Keller, J.1
Trautmann, M.E.2
Haber, H.3
-
60
-
-
84871564295
-
Direct effect of GLP-1 infusion on endogenous glucose production in humans
-
Seghieri M, Rebelos E, Gastaldelli A, et al. Direct effect of GLP-1 infusion on endogenous glucose production in humans. Diabetologia 2013;56:156-61.
-
(2013)
Diabetologia
, vol.56
, pp. 156-161
-
-
Seghieri, M.1
Rebelos, E.2
Gastaldelli, A.3
-
61
-
-
27744541052
-
Exenatide augments first-and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes
-
Fehse F, Trautmann M, Holst JJ, et al. Exenatide augments first-and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2005;90:5991-7.
-
(2005)
J Clin Endocrinol Metab
, vol.90
, pp. 5991-5997
-
-
Fehse, F.1
Trautmann, M.2
Holst, J.J.3
-
62
-
-
78650507366
-
GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons
-
Griffioen KJ, Wan R, Okun E, et al. GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons. Cardiovasc Res 2011;89:72-8.
-
(2011)
Cardiovasc Res
, vol.89
, pp. 72-78
-
-
Griffioen, K.J.1
Wan, R.2
Okun, E.3
-
63
-
-
2942668372
-
Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men
-
Gutzwiller J-P, Tschopp S, Bock A, et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 2004;89:3055-61.
-
(2004)
J Clin Endocrinol Metab
, vol.89
, pp. 3055-3061
-
-
Gutzwiller, J.-P.1
Tschopp, S.2
Bock, A.3
|